Open AccessP765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1‐MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS)
Author(s) -
DiNardo C. D.,
Foran J. M.,
Watts J. M.,
Stein E. M.,
Botton S.,
Fathi A. T.,
Prince G. T.,
Stone R. M.,
Patel P. A.,
Roboz G. J.,
Arellano M. L.,
Erba H. P.,
Pigneux A.,
Baratam P.,
Stuart R. K.,
Thomas X.,
Lemieux I. R.,
Bai X.,
Kapsalis S. M.,
GarciaManero G.,
Sallman D. A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845944.18977.d1
Subject(s) - medicine , idh1 , tolerability , myelodysplastic syndromes , isocitrate dehydrogenase , refractory (planetary science) , oncology , international prognostic scoring system , myeloid leukemia , gastroenterology , adverse effect , bone marrow , physics , astrobiology , gene , biochemistry , chemistry , enzyme , mutation